Manhattan Scientifics' Technology Able to Detect Breast Cancer Three Years Earlier Than Mammogram

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Manhattan Scientifics, Inc. (OTCBB: MHTX) announced today that its "early cancer detection" technology, developed by Edward R. Flynn, Ph.D. is expected to identify breast cancer three years earlier than the current gold standard mammogram test. Dr. Flynn is a pioneer in the emerging field of nano medicine.

When fully developed and commercialized, Dr. Flynn's biomagnetic-based system will be 100% radiation free, unlike current radiation-based mammogram tests. Manhattan Scientifics is currently seeking a partner to commercialize the technology.

To reduce harm from over-treatment and radiation, new medical guidelines recently issued by the U.S. Preventive Services Task Force recommended that women begin regular breast cancer screening at age 50, rather than age 40. "Annual mammograms for most women in their 40's have more drawbacks than benefits...." according to an article published by Bloomberg News, November 17, 2009.

CEO Manny Tsoupanarias said, "We believe early detection of cancer can be critical to effective treatment. Current mammography cannot detect a breast cancer tumor until it has grown to over ten million cells. Dr. Flynn's technology has proven the ability to detect breast cancer tumors only 1% that large, resulting in a hundred-fold increase in sensitivity and early detection.

"The new technology has demonstrated similar early detection performance for ovarian cancer, a cancer that currently has no effective screening techniques. Our technology also demonstrated effectiveness in monitoring chemotherapy for leukemia, allowing more effective treatment with fewer side effects. Dr. Flynn's work has been supported for eight years by nine grants from the National Institutes of Health and a grant from the U.S. Department of Defense. The technology is protected by issued and pending patents," Tsoupanarias said

source: Manhattan Scientifics Inc.

Montgomery Breast Center First To Install Breast Cancer Lesion-Localization System

The Montgomery Breast Center of Montgomery, Ala., is the first center in the country to install and use the GammaLoc® lesion-localization system. This system is the only FDA-cleared device that enables gamma-guided, minimally invasive needle biopsy of suspicious lesions identified with Breast-Specific Gamma Imaging (BSGI). BSGI is performed by the Dilon 6800®, a gamma camera that is optimized to reveal lesions independent of tissue density and discover early stage cancers that are oftentimes not identified with other imaging methods, such as mammography, ultrasound and magnetic resonance imaging (MRI).

GammaLoc® helps the physician calculate the specific depth and location of the suspect lesion. A computer user interface with detailed step-by-step instructions guides the physician through the biopsy procedure. The GammaLoc® system utilizes a CorreLocator™ paddle and a StereoView™ imaging collimator system a technique similar to that used in stereotactic X-ray localization.

source: Medical News Today

Innovation in Mathematics Leads to Revolutionary Breast Imaging System

TechniScan's scientific breakthrough in Inverse Scattering presented to doctors and scientists at AIUM conference

SALT LAKE CITY, April 7 /PRNewswire-FirstCall/ -- The groundbreaking algorithms developed at TechniScan, Inc. (OTC Bulletin Board: TSNI) have led to a new arena of whole breast ultrasound technology, as presented at a national medical ultrasound conference in San Diego in March.

TechniScan cofounder and scientist-mathematician, James Wiskin, Ph.D. spoke at the American Institute of Ultrasound Medicine (AIUM) conference held at the San Diego Marriott Hotel and Marina about the unique methods in which the company's 3-dimensional whole breast ultrasound captures anatomical images of the breast.

The breakthrough in imaging is a result of Wiskin's and colleagues David Borup, Ph.D., and Steven Johnson's, Ph.D. work in the mathematics of inverse scattering. TechniScan's Warm Bath Ultrasound™ (WBU) system uses a unique combination of traditional B-mode (reflective) ultrasound and two types of transmission ultrasound – speed of sound and attenuation of sound, to produce three unique sets of images.

"This revolutionary new method of imaging produces information not available with traditional reflection ultrasound or whole breast ultrasound as it is presently being developed. Uniquely, we can also capture 360 degree compounded coronal images," said Wiskin.

source: PR Newswire

Pioneering Breast Scanner Holds Great Promise for Accurately Detecting and Diagnosing Breast Cancer at Its Earliest Stages

CHARLOTTESVILLE, Va., April 1, 2010 - Perhaps no one can appreciate the importance of early cancer detection as much as Izora Armstrong. That's because UVA Cancer Center researchers, using a first-of-its-kind hybrid breast imaging device, found what mammography, ultrasound, MRI and even a needle biopsy couldn't.

"I feel truly blessed that I came to UVA, that they gave me the chance to be a part of this study," says Armstrong, 53, a school bus driver in southern Fauquier County. "I went through all the regular tests and did what women are supposed to do and I still wouldn't have known I had breast cancer if it wasn't for UVA."

The unique device, the dual modality tomographic (DMT) breast scanner, developed by UVA researchers, has shown in its pilot study the ability to pinpoint to a much finer degree the exact location of breast masses - and, even more important, to more accurately distinguish between cancerous and harmless lesions.

The pilot clinical study, led by Mark B. Williams, PhD, associate professor of radiology, biomedical engineering and physics at the University of Virginia, appears in the April 2010 issue of Radiology.

The DMT breast scanner works by marrying two cutting-edge imaging methods, one that obtains 3-D anatomical (structural) imaging and another that obtains 3-D biological (functional) imaging, into one integrated device. The machine runs the scans sequentially, obtaining both types of images with the breast in the same, immobilized position.

source: University of Virginia Health System